

**THE MCKNIGHT ENDOWMENT FUND FOR NEUROSCIENCE**  
**FINANCIAL STATEMENTS**  
**YEARS ENDED DECEMBER 31, 2024 AND 2023**



CPAs | CONSULTANTS | WEALTH ADVISORS

[CLAconnect.com](https://CLAconnect.com)

**THE MCKNIGHT ENDOWMENT FUND FOR NEUROSCIENCE  
TABLE OF CONTENTS  
YEARS ENDED DECEMBER 31, 2024 AND 2023**

<b>INDEPENDENT AUDITORS' REPORT</b>	<b>1</b>
<b>FINANCIAL STATEMENTS</b>	
<b>STATEMENTS OF ASSETS AND NET ASSETS WITHOUT RESTRICTIONS         – CASH BASIS</b>	<b>3</b>
<b>STATEMENTS OF REVENUES, EXPENSES, AND CHANGES IN NET         ASSETS WITHOUT RESTRICTIONS – CASH BASIS</b>	<b>4</b>
<b>STATEMENTS OF FUNCTIONAL EXPENSES – CASH BASIS</b>	<b>5</b>
<b>NOTES TO FINANCIAL STATEMENTS</b>	<b>6</b>



## INDEPENDENT AUDITORS' REPORT

Board of Directors  
The McKnight Endowment Fund for Neuroscience  
Minneapolis, Minnesota

### Report on the Audit of the Financial Statements

#### ***Opinion***

We have audited the accompanying financial statements of The McKnight Endowment Fund for Neuroscience (the Fund) (a nonprofit organization), which comprise the statements of assets and net assets without restrictions – cash basis as of December 31, 2024 and 2023, and the related statements of revenues, expenses, and changes in net assets without restrictions – cash basis and functional expenses – cash basis for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the assets and net assets without restrictions of The McKnight Endowment Fund for Neuroscience as of December 31, 2024 and 2023, and its revenues and expenses for the years then ended in accordance with the cash basis of accounting as described in Note 1.

#### ***Basis for Opinion***

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We are required to be independent of The McKnight Endowment Fund for Neuroscience and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### ***Basis of Accounting***

We draw attention to Note 1 of the financial statements, which describes the basis of accounting. The financial statements are prepared on the cash basis of accounting, which is a basis of accounting other than accounting principles generally accepted in the United States of America. Our opinion is not modified with respect to that matter.

#### ***Responsibilities of Management for the Financial Statements***

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the cash basis of accounting, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

***Auditors' Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of The McKnight Endowment Fund for Neuroscience's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about The McKnight Endowment Fund for Neuroscience's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.



**CliftonLarsonAllen LLP**

Minneapolis, Minnesota  
August 7, 2025

**THE MCKNIGHT ENDOWMENT FUND FOR NEUROSCIENCE**  
**STATEMENTS OF ASSETS AND NET ASSETS WITHOUT RESTRICTIONS – CASH BASIS**  
**DECEMBER 31, 2024 AND 2023**

	<u>2024</u>	<u>2023</u>
<b>ASSETS, CASH</b>	<u>\$ 20,286</u>	<u>\$ 25,588</u>
<b>NET ASSETS WITHOUT RESTRICTIONS</b>	<u>\$ 20,286</u>	<u>\$ 25,588</u>

*See accompanying Notes to Financial Statements.*

**THE MCKNIGHT ENDOWMENT FUND FOR NEUROSCIENCE**  
**STATEMENTS OF REVENUES, EXPENSES, AND**  
**CHANGES IN NET ASSETS WITHOUT RESTRICTIONS – CASH BASIS**  
**YEARS ENDED DECEMBER 31, 2024 AND 2023**

	<u>2024</u>	<u>2023</u>
<b>REVENUES</b>		
Grants Received	\$ 3,845,550	\$ 3,800,550
<b>EXPENSES</b>		
Program:		
Neurobiology of Brain Disorders Awards Program	1,223,690	1,122,690
Scholars Awards Program	1,981,470	1,762,900
Technological Innovations in Neuroscience Awards Program	2,000	301,000
Pecot Awards	99,000	82,413
Annual Neuroscience Conference	394,966	380,575
Total Program Expenses	<u>3,701,126</u>	<u>3,649,578</u>
Administrative Expenses	<u>149,726</u>	<u>149,815</u>
Total Expenses	<u>3,850,852</u>	<u>3,799,393</u>
<b>CHANGE IN NET ASSETS</b>	(5,302)	1,157
Net Assets Without Restrictions – Beginning of Year	<u>25,588</u>	<u>24,431</u>
<b>NET ASSETS WITHOUT RESTRICTIONS – END OF YEAR</b>	<u><u>\$ 20,286</u></u>	<u><u>\$ 25,588</u></u>

See accompanying Notes to Financial Statements.

**THE MCKNIGHT ENDOWMENT FUND FOR NEUROSCIENCE**  
**STATEMENTS OF FUNCTIONAL EXPENSES – CASH BASIS**  
**YEARS ENDED DECEMBER 31, 2024 AND 2023**

	2024		
	Program	Management and General	Total
Awards	\$ 3,247,889	\$ -	\$ 3,247,889
Board and Committee Fees	46,000	23,000	69,000
Meeting and Travel Expenses	397,645	86	397,731
Professional Services	3,742	100,000	103,742
Annual Audit and Tax Return	-	12,544	12,544
Computer Services	-	13,850	13,850
Communication	5,850	135	5,985
Other Expenses	-	111	111
Total Expenses	<u>\$ 3,701,126</u>	<u>\$ 149,726</u>	<u>\$ 3,850,852</u>

  

	2023		
	Program	Management and General	Total
Awards	\$ 3,207,413	\$ -	\$ 3,207,413
Board and Committee Fees	44,000	22,000	66,000
Meeting and Travel Expenses	386,523	4,107	390,630
Professional Services	5,655	100,000	105,655
Annual Audit and Tax Return	-	9,885	9,885
Computer Services	-	13,267	13,267
Communication	5,850	536	6,386
Other Expenses	137	20	157
Total Expenses	<u>\$ 3,628,288</u>	<u>\$ 149,815</u>	<u>\$ 3,799,393</u>

See accompanying Notes to Financial Statements.

**THE MCKNIGHT ENDOWMENT FUND FOR NEUROSCIENCE**  
**NOTES TO FINANCIAL STATEMENTS**  
**DECEMBER 31, 2024 AND 2023**

**NOTE 1 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Nature of Business**

The McKnight Endowment Fund for Neuroscience (the Fund) is a private foundation incorporated under the laws of Minnesota. The Fund is an independent charitable organization established by The McKnight Foundation (the Foundation) to support innovative research in neuroscience through four competitive annual awards and an annual conference.

**Basis of Accounting**

The financial statements of the Fund are maintained on a cash basis, and the statements of revenues, expenses, and changes in net assets without restrictions – cash basis and the statements of assets and net assets without restrictions – cash basis reflect only cash received and disbursed. Therefore, grants receivable and payable, accounts payable, and accrued income and expenses, which may be material in amount, are not reflected in the accompanying financial statements, which are not intended to present financial position and results of activities in conformity with accounting principles generally accepted in the United States of America.

**Financial Statement Presentation**

Net assets and revenues, gains, and losses are classified based on donor-imposed restrictions. There are no donor-imposed restrictions, and the board of directors has discretionary control over the resources. Accordingly, net assets of the Fund and changes therein are classified and reported as without restrictions.

**Tax-Exempt Status**

The Fund is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC). The Fund is classified as a private foundation as defined in Section 509(a) and 4940 of the IRC and as such is subject to certain minimum distribution requirements. No taxes were paid during the years ended December 31, 2024 and 2023.

The Fund follows a policy that clarifies the accounting for uncertainty in income taxes recognized in an organization's financial statements. The policy prescribes a recognition threshold and measurement principles for the financial statement recognition and measurement of tax positions taken or expected to be taken on a tax return that are not certain to be realized. The implementation of this policy had no impact on the Fund's financial statements.

**Functional Allocation of Expenses**

The costs of providing programs and services have been summarized on a functional and natural basis. Specifically identifiable expenses have been allocated to program and management and general, respectively. Other expenses, not specifically identifiable, have been allocated to program and management and general expenses based upon best estimates of management.



**THE MCKNIGHT ENDOWMENT FUND FOR NEUROSCIENCE**  
**NOTES TO FINANCIAL STATEMENTS**  
**DECEMBER 31, 2024 AND 2023**

**NOTE 1 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**  
**(CONTINUED)**

**Subsequent Events**

In preparing these financial statements, the Fund has evaluated events and transactions for potential recognition of disclosure through August 7, 2025, the date the financial statements were available to be issued.

**NOTE 2 LIQUIDITY AND AVAILABILITY**

Because its records are maintained on a cash basis, the Fund's only financial asset is cash held in a checking account. To meet its current financial obligations, the Fund receives its annual funding of approximately \$3.8 million from the Foundation in four to six installments per year, as needed.

**NOTE 3 CASH BALANCE**

At December 31, 2024 and 2023, cash was maintained in a checking account that, at times during the years then ended, exceeded federally insured limits. The Fund has not experienced any losses in such accounts.

**NOTE 4 RELATED PARTY TRANSACTIONS**

The Foundation has approved grant funding to the Fund annually through 2032 for the purposes of funding and administering neuroscience awards. The Foundation, upon which the Fund solely relies for grant funding, has the ability to appoint three of the eleven members of the Fund's board of directors. During 2024 and 2023, \$3,845,550 and \$3,800,550 of grants were received by the Fund, respectively. The Foundation grants to be received by the Fund are as follows as of December 31:

	2024	2023
Less Than One Year	\$ 3,800,550	\$ 3,800,550
One Year to Five Years	16,402,700	16,402,700
Greater Than Five Years	10,150,650	13,996,200
Total	<u>\$ 30,353,900</u>	<u>\$ 34,199,450</u>

Pursuant to an administrative agreement, the Fund reimbursed the Foundation \$100,000 for each of the years ended December 31, 2024 and 2023 for administrative services provided by the Foundation.

For the years ended December 31, 2024 and 2023, payments have been made to board members for their services as board members in the amount of \$36,000 and \$34,000, respectively.

**THE MCKNIGHT ENDOWMENT FUND FOR NEUROSCIENCE**  
**NOTES TO FINANCIAL STATEMENTS**  
**DECEMBER 31, 2024 AND 2023**

**NOTE 5 GRANT COMMITMENTS**

At both December 31, 2024 and 2023, the Fund's board of directors had approved grants of \$3,949,000 and \$3,932,500 to be paid through 2024, 2025, 2026, and 2027, respectively. Payments of approved grants are expected to be funded by proceeds of grants from the Foundation. Grant payments, net of returned grant funds, during the years ended December 31, 2024 and 2023 were \$3,247,889 and \$3,207,413, respectively.

**NOTE 6 NEUROSCIENCE CONFERENCE COMMITMENTS**

In 2023, the Fund has signed a contract for the 2025 and 2026 Neuroscience Conferences. The Fund will be liable for up to approximately \$232,000 and \$269,000 respectively if the conferences are cancelled before the scheduled conference date.



CLA (CliftonLarsonAllen LLP) is a network member of CLA Global. See [CLAGlobal.com/disclaimer](http://CLAGlobal.com/disclaimer). Investment advisory services are offered through CliftonLarsonAllen Wealth Advisors, LLC, an SEC-registered investment advisor.